Antiangiogenic agents and their promising potential in combined therapy

Critical Reviews in Oncology/Hematology

Volumn 39, Issue 1-2, 2001, Pages 155-171

  Burke, Patricia A ^a   DeNardo, Sally J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Antiangiogenic therapy; Cancer; Radioimmunotherapy

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; CELGENE; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; INTEGRIN; MARIMASTAT; PRINOMASTAT; THALIDOMIDE; UNCLASSIFIED DRUG;

ANGIOGENESIS; CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER THERAPY; CELL MIGRATION; CELL PROLIFERATION; CONFERENCE PAPER; DRUG DESIGN; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; METASTASIS; NONHUMAN; RADIOIMMUNOTHERAPY; SOLID TUMOR; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ENDOTHELIUM, VASCULAR; HUMANS;

EID: 0034975263     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00115-9     Document Type: Conference Paper

References (167)

1. Tumor angiogenesis and the role of vascular cell integrin αvβ3
2. Angiogenesis and anti-angiogenesis: perspectives for the treatment of solid tumors
3. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
4. The preclinical evaluation of angiogenesis inhibitors
5. Tumor angiogenesis: therapeutic implications
6. Anti-angiogenesis: new concept for therapy of solid tumors
7. Vascular endothelium as the vulnerable element in tumours
8. Tumor angiogenesis: past, present and the near future
9. Barriers to drug delivery in solid tumors
10. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy
11. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy
12. Openings between defective endothelial cells explain tumor vessel leakiness
13. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents
14. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
15. The rationale and future potential of angiogenesis inhibitors in neoplasia
16. Antiangiogenic tumour therapy: will it work?
17. Angiostatin induces and sustains dormancy of human primary tumors in mice
18. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody
19. Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor
20. Intratumor microvessel density as a prognostic factor in cancer
21. Angiogenesis and oxygen transport in solid tumors
22. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma
23. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
24. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis
25. Critical determinants of cancer metastasis: rationale for therapy
26. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogensis suppression
27. Tumor angiogenesis: biology and therapeutic prospects
28. Tumor vasculature targeted therapies
29. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
30. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implication for antiangiogenic tumor therapies
31. Review: the integrin αvβ3: angiogenesis and apoptosis
32. Requirement of vascular integrin alpha v beta 3 for angiogenesis
33. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
34. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines
35. Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells
36. Regulation of angiogenesis via vascular endothelial growth factor receptors
37. Role of vascular endothelial growth factor in regulation of angiogenesis
38. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis
39. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
40. Flk-1 as a target for tumor growth inhibition
41. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer
42. Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation
43. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library
44. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
45. SU5416 inhibits the tyrosine kinase vascular endothelial growth factor receptor Flt-1 in vitro and angiogenesis in vivo
46. SU6668, A broad spectrum angiogenesis inhibitor, exhibits potent activity against established tumors in diverse mouse xenograft models
47. A novel angiogenesis inhibitor, SU00668, strongly exhibiting in vivo cancer activity
48. VEGF receptor tyrosine kinase inhibitors as potential anti-tumor agents
49. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy
50. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors
51. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
52. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy
53. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders
54. Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans
55. Vascular endothelial growth factor receptor (VEGFR-2) antibody therapy combined with conventional chemotherapy inhibits growth of established tumors in mice
56. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatements with an anti-VEGF neutralizing monoclonal antibody and doxorubicin
57. Antiangiogenesis is produced by nontoxic doses of vinblastine
58. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
59. Dose and frequency modification of conventional chemotherapeutic regimen has anti-angiogenic effects and, when combined with anti-fli1 monoclonal antibody, results in full xenograft regression, no toxicity and circumvention of drug resistance
60. A phase I/II trial and pharmacokinetic (PK) study of the vascular endothelial growth factor (VEGF) receptor pathway inhibitor SU5416 in combination with paclitaxel
61. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor
62. Dynamics of tumor oxygenation, CD31 staining and transforming growth factor-( levels after treatment with radiation or cyclophosphamide in the rat 13762 mammary carcinoma
63. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth
64. Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent
65. Multi-institutional study of the angiogenesis inhibito TNP-470 in metastatic renal carcinoma
66. Fumagillin analogue in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study, AIDS Clinical Trial Group No. 215 Team
67. TNP-470 (AGM-1470): mechanisms of action and early clinical development
68. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP2
69. TNP-470
70. Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo
71. Inhibition of liver metastasis of human gastric carcinoma by angiogenesis inhibitor TNP-470
72. Therapeutic synergy of TNP-470 and Ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts
73. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
74. Potentiation of cytotoxic cancer therapies by antiangiogenic agents
75. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470)
76. Angiogenesis inhibition by minocycline
77. Suramin, an inhibitor of angiogenesis, suppresses endothelial cell growth, migration and plasminogen activator activity
78. Genistein, a dietary-derived inhibitor of in vitro angiogenesis
79. Suramin: an anticancer drug with a unique mechanism of action
80. Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo
81. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with antiangiogenic agents
82. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents
83. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma
84. TNP-470/miocyclin/cytotoxic therapy: a systems approach to cancer therapy
85. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease
86. An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma
87. Thalidomide is an inhibitor of angiogenesis
88. Thalidomide and analogs
89. Thalidomide: a prodrug that inhibits angiogenesis
90. Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitors
91. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
92. Pharmacokinetics of thalidomide in an elderly prostate cancer population
93. The effect of thalidomide on experimental tumors and metastases
94. Thalidomide and chemotherapy combination: preliminary results of preclinical and clinical studies
95. An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action
96. Down-regulation of adhesion receptors on cells of primate embryos as a probable mechanism of the teratogenic action of thalidomide
97. Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits
98. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent
99. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
100. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer
101. Angiostatin and other plasminogen fragments
102. Human angiostatin inhibits murine hemangioendothelioma tumor growth
103. Angiostatin binds ATP synthase on the surface of human endothelial cells
104. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD
105. Angiostatin diminishes activation of the mitogen-activated protein kinases ERK-1 and ERK-2 in human dermal microvascular endothelial cells
106. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation
107. Combined effects of angiostatin and ionizing radiation in autitumour therapy
108. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy
109. Therapeutic potentials of angiostatin in the treatment of cancer
110. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin
111. Endostatin induces endothelial apoptosis
112. Endostatin inhibits VEGF-induced endothelial migration and tumor growth independently of zinc binding
113. Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors
114. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
115. Synergy between angiostatin and endostatin, inhibition of ovarian cancer growth
116. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials
117. Matrix metallproteinases in angiogenesis: a moving target for therapeutic intervention
118. Anticancer drug targets: approaching angiogenesis
119. Matrix metalloproteinase inhibitors
120. Matrix metalloproteinase inhibitors
121. Antiangiogenic agents
122. Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma
123. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts
124. Clinical trials of angiogenic agents
125. Batmastat and marmastat in cancer: summary of early clinical data
126. Marimastat (BB2516): current status of development
127. Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen
128. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer
129. Rocking the foundations of solid tumor growth by attacking the tumor's blood supply
130. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies
131. In vivo and in vitro invasiveness of human lung carcinoma lines
132. Integrins and cancer
133. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
134. The role of vascular cell integrins αvβ3 and αvβ5 in angiogenesis
135. Vascular expression of the alpha(v)beta(3)-integrin in lung and other organs
136. An antagonist of integrin alpha v beta 3 prevents maturation of blood vessels during neovascularization
137. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin αvβ3 during angiogenesis
138. Definition of two angiogenic pathways by distinct αv integrins
139. Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging
140. Stepwise in vitro affinity maturation of vitaxin, an αvβ3-specific humanized mAb, Proceedings of the National Academy of Science
141. The role of αv integrins during angiogenesis: insights into potential mechanisms of action and clinical development
142. Structural and functional aspects of RGD containing cyclic pentapeptides as highly potent and selective integrin alpha(V)beta(3) antagonists
143. N-methylated cyclic RGD peptides as highly active and selective avb3 integrin antagonists
144. Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting
145. Synergy between an anti-angiogenic intergrin v antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases
146. T cell-mediated eradiacation of murine metastatic melanoma induced by targeted interleukin 2 therapy
147. Design of superactive and selective integrin receptor antagonists containing the RGD sequence
148. Stereoisomerism and biological activity of the selective and superactive αvβ3integrin inhibitor cyclo-(-RGDfV-) and its retroinverso peptide
149. Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy
150. Requirement of vascular integrin alpha v beta for angiogenesis
151. Antiintegrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin
152. Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas [published erratum appears in Int J Cancer Aug 7;72(4):706-7]
153. Studies on alpha v beta 3/ligand interactions using a [3H]SK&F-107260 binding assay
154. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
155. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature
156. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells
157. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry
158. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis
159. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
160. Vasculogenic mimicry and tumor angiogenesis
161. Gene therapy strategies for tumor antiangiogenesis
162. Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA
163. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene
164. Endpoints for determination of efficacy of antiangiogenic agents in clinical trials
165. Less is more, regularly: metronomic dosing of cytotoxic drugs
166. A new era for radiolabeled antibodies in cancer?